Background: A hematocrit (HCT)-based and a body surface area (BSA)-based equations were applied for plasma volume (PV) estimation, respectively, to confirm and quantify the hemodilution effect in prostatespecific antigen (PSA) screening among obese men. The agreement between the equations was additionally investigated.
Introduction
It has been reported (1-3) that lower serum prostatespecific antigen (PSA) levels among obese men suggest that obesity might have a negative effect on screening for prostate cancer by lowering serum PSA levels of these men. Recent studies (3) (4) (5) showed that although PSA concentration decreased significantly with the increase of body mass index (BMI), the estimated PSA mass did not, indicating that the lower PSA concentration observed in obese men could be merely because of the fact that men with greater BMI also tended to have larger plasma volume (PV). In these studies, estimated PV and PSA mass were based on a body surface area (BSA) equation. However, a recent study indicated that there are significant variation in the PV calculated by different BSAbased equations, which are further magnified in the sequential calculation of PSA mass (6) . Here, another equation for PV estimation was proposed, which has not been chosen in similar studies before but widely applied for drug administration, with a new introduced variable hematocrit (HCT%; refs. 6, 7):
Meanwhile, a commonly chosen BSA-based formula (3-5) appended later was applied for method comparison:
We are going to investigate:
1. The evidence of hemodilution effect among obese men and the implications for PSA screening; 2. The agreement between the estimates by using the HCT-based (7, 8) and the BSA-based (3) (4) (5) equations.
Patients and Methods

Participants selection
This was a retrospective study of participants presenting at our unit for health management from May to November 2008. A total of 4,312 consecutive males, ages 40 to 65 years, underwent a physical examination during the initial consultation. The information obtained was then prospectively collected in a computer database. After 3 years (May 2009 to November 2011), follow-ups were done once in a year for this cohort. We excluded participants with missing data due to rejection of uncomfortable examinations, including digital rectal examination and blood collection, or unselection of the items by self-funded participants, or having part of the laboratory examinations detected recently in another clinical center with unshared results. The missing data were detailed as follows: missing BMI (75 cases), absence of HCT (295 cases) or serum PSA concentration (1,037 cases), no recorded history of benign prostate problems (1,174 cases), no data of alanine aminotransferase (ALT; 342 cases), aspartate aminotransferase (AST; 342 cases), or serum creatinine (Cr; 183 cases). There were overlaps among these missing data. People with one of the following criteria were additionally excluded:
1. PSA concentration higher than 4 ng/mL (92 cases); 2. Confirmed prostate cancer previously or within the 3-year follow-up (5 cases); 3. The use of medication affecting PSA concentration (82 cases); 4. A previous surgical procedure related to benign prostate problem (30 cases).
The remaining 1,444 males without clinically detectable prostate cancer were included in the present analysis. Our local Institutional Review Board approved the survey before it was conducted.
Clinical variables
Standing height and weight were measured with emptied pockets and without shoes; the BMI was calculated as usual. Subjects were divided into 2 BMI categories of 27.4 or less and !27.5 or more according to the new Asian classification (9) . The HCT was measured on a Hematology Analyzer (Beckman COULTER GEN'S System 2); ALT, AST, and serum Cr on a Hitachi 7600 modular chemistry analyzer; serum PSA concentration on a Beckman Coulter DXI 800 Immunoassay Analyzer. All the above assessments were measured by qualified staffs at our health management center. PVs and PSA masses were estimated by using the earlier described equations (3-5, 7, 8) .
Statistical analyses
Statistical analyses were conducted by using the SPSS 13.0 software. PSA and PSA mass were logarithmically transformed to provide a more normal data distribution.
Multivariable linear regression models were conducted to investigate the changes of PV, PSA concentration, and masses estimated by respective equations with the increasing of BMI. Age was adjusted in the model when PV was defined as a dependent variable. Benign prostate problems, AST, ALT, and Cr were additionally adjusted with PSA or mass as dependent variable, as it was shown that these independent variables might contribute to the changes of PSA concentration or mass in previous literatures (3, 10) .
A mathematical model was established for the calculation of a serum PSA level in an obese man that corresponds to a PSA of 4.0 ng/mL in a nonobese man (5) . The geometric means of height, weight, and HCT were obtained for the nonobese and obese group, respectively, to calculate the PV of each group (PV Nonobese and PV Obese ). As PSA mass was assumed to be consistent according to BMI group in healthy cohorts (3, 5) , an equation can be extrapolated: the cutoff value of PSA concentration predicted for an obese man in this cohort ¼ 4.0 ng/mL Â PV Nonobese /PV Obese . The HCT-based and BSA-based PVs were put into the model, respectively.
To analyze the agreement between the 2 equations for PV estimation, Bland and Altman method was additionally conducted (11) .
Results Figure 1 shows a distribution of men by BMI and PSA for the whole cohort. Table 1 shows the relationships among PSA concentration, PV, PSA mass, and BMI. Approximately 17.7% of males were classified as obese. When BMI was analyzed as a continuous variable, logarithmically transformed PSA levels were inversely associated with BMI significantly (b ¼ À0.011, P < 0.001). Means of estimated PVs by using HCT-and BSA-based equations, increased with increasing BMI category, from 2.65 L in nonobese men to 3.18 L in obese men, and from 3.03 to 3.28 L, respectively (P < 0.05). The sequentially estimated PSA masses, however, did not show a The mathematical modeling procedures by using the obtained geometric means of weight, height, and HCT, showed that a PSA concentration of 4 ng/mL in nonobese group equates to a PSA masses of 10.52 mg (4 ng/mL Â 2.63 L) by using HCT-based PV and 12.08 mg (4 ng/mL Â 3.02 L) by BSA-based equation. Respective PVs of 3.19 and 3.28 L for obese group were also obtained according to the methods mentioned earlier, resulting in 2 cutoff PSA concentrations for obese men, 3.32 and 3.68 ng/mL.
Bland and Altman plot was used to examine how the means of PV between the 2 formulae changed relative to their difference (Fig. 2) . The BSA-based formula produced higher bias at a low PV (overestimation) than that from HCT-based equation [mean (95% confidence interval) difference: 0.33 (À0.06 to 0.73) L; r ¼ À0.542, P < 0.001). In fig. 2 , there were 67 data points (bias) beyond the AE1.96 SD limits. The maximum difference between the 2 equations was 0.89 L.
Discussion
We have confirmed in this Chinese cohort the widely reported inverse association between PSA levels and BMI (12) . Specifically, 2 equations, based on HCT and BSA, respectively, are selected for PV and PSA mass estimation. The results obtained by both equations indicated that although PSA concentration decreased with the increasing BMI, however, PSA mass remained consistent. This suggests that hemodilution from larger PV may be responsible for the lower PSA values observed among obese men. Also, in 2 mathematical models by using HCTand BSA-based equations for PV estimation, serum PSA concentrations of 3.32 and 3.68 ng/mL in obese men that correspond to a screening PSA of 4.0 ng/mL in nonobese men were predicted, respectively. The latter was consistent with the study done by Rundle and Neugut' (3.65 ng/mL; ref. 5) by using the same BSA-based equation, whereas the former one seemed to be lower. That might be because of the overestimation of the dilution power of PV estimated by the HCT-based equation and underestimation of that calculated by BSA-based formula when compared with mean PV. The "real" cutoff value for obese men might just lie between the 2 values.
For further discussion on the problem, the agreement between the HCT-and BSA-based equations for PV estimation was investigated. The Bland and Altman plot displays considerable lack of agreement between the 2 equations, with discrepancies of PV up to 890 mL, which will undoubtedly be greatly magnified in the sequential calculation of PSA mass. Because of the absence of PV determined by "Golden criteria," we could not tell which equation is more suitable for clinical application. However, the discrepancies call for greater attention to further study on the problem. One alternative explanation for the decreased PSA concentration seen in the obese men may be a decrease in circulating levels of androgens that are more likely to be found in obese men (13) . However, previous studies have shown that only for hypogonadal men, who underwent testosterone replacement treatment, PSA levels increases (14) . Although for healthy young men suffering testosterone administration, PSA did not change (15) . The earlier data might indicate that the influence of testosterone on PSA level is not consistent and maybe dependent on the gonad function. Moreover, given that PSA is under androgenic control, obese men would be expected to have lower PSA mass. However, several studies, including ours, confirm that obese men had similar or even higher PSA mass in cohorts of both healthy males and patients with prostate cancer (3, 4) . On the basis of these studies, we proposed that the PSA level might be mainly controlled by both hormones and hemodilution, which might be useful for explaining the conflicting results on the relationship between BMI and PSA found in other studies (16, 17) . Our data support that in the present cohort, hemodilution predominates and that hormonal effects are rendered negligible. Unfortunately, we do not have testosterone levels in all of the men in the cohort, and further studies are still needed to test the effects of hormones on PSA level.
Conclusions
The inverse relationship between PSA concentration and BMI might be explained by a hemodilution effect among obese men. There is significant variation in the PV calculated by the 2 equations.
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